Conference
Update in Lung Transplantation: Indications and Outcomes « Foch Hospital Experience, in France »
Abstract
Lung transplantation has become an acceptable treatment for end-stage respiratory failure, without alternative treatment.
Since the first lung transplantation in 1963, there has been great progress in the management of patients with lung transplantation.
The volume of transplanted patients in the world has increased, due to medical and surgical progress, modality of emergency lung transplantation, and ex-vivo use.
And we have very good results in terms of survival and quality of life despite the difficulty in treating patients with the occurrence of complications, particularly infectious, immunological, chronic graft dysfunction, and others.
A median survival in some centres approaches 10 years.
According to international ISHLT registry, there are over 15,000 lung transplants worldwide.
Overall survival is 80% at one year, 75% at five years, 50% at 10 years and 30% at 20 years.
At Foch Hospital, we have 35 years of experience in lung transplantation program with improvement in several periods between 1989 and 2024, 1276 patients were transplanted, and 54% of them are still alive.
Global survival at 3 months, 1 years, 5 years, 10 years, 15 years, and 20 years was 89,4%, 83.5%, 65.5%, 49%, 39%, and 21 % respectively.
Patients with cystic fibrosis have a better 5-year survival (72%) than those with emphysema or pulmonary fibrosis (72 % vs. 64 % for emphysema and 54% for fibrosis).
Survival is further improved in the last 10 years (January 2015 - October 2024, cohort of 641), at 1 year : 85% for pulmonary fibrosis, 90% for emphysema, and 93% for cystic fibrosis.
Emergency transplantation had a 60% 5-year survival.
Conclusion. — The thirty-five years of experience shows a consistent improvement in the results of lung transplantation which is now accepted as the only effective curative treatment for end stage lung disease.
These results show the effectiveness of our group and encourage us to continue the lung transplantation program and transmit our knowledge and training to other teams around the world.
Prof. Dr Abdul Monem HAMID
Foch University Hospital
Department of Pulmonary Medicine and Lung Transplantation
Suresnes, Paris
Université de Versailles Saint-Quentin-en-Yvelines, Paris
Paris Hospitals College of Medicine
France
Since the first lung transplantation in 1963, there has been great progress in the management of patients with lung transplantation.
The volume of transplanted patients in the world has increased, due to medical and surgical progress, modality of emergency lung transplantation, and ex-vivo use.
And we have very good results in terms of survival and quality of life despite the difficulty in treating patients with the occurrence of complications, particularly infectious, immunological, chronic graft dysfunction, and others.
A median survival in some centres approaches 10 years.
According to international ISHLT registry, there are over 15,000 lung transplants worldwide.
Overall survival is 80% at one year, 75% at five years, 50% at 10 years and 30% at 20 years.
At Foch Hospital, we have 35 years of experience in lung transplantation program with improvement in several periods between 1989 and 2024, 1276 patients were transplanted, and 54% of them are still alive.
Global survival at 3 months, 1 years, 5 years, 10 years, 15 years, and 20 years was 89,4%, 83.5%, 65.5%, 49%, 39%, and 21 % respectively.
Patients with cystic fibrosis have a better 5-year survival (72%) than those with emphysema or pulmonary fibrosis (72 % vs. 64 % for emphysema and 54% for fibrosis).
Survival is further improved in the last 10 years (January 2015 - October 2024, cohort of 641), at 1 year : 85% for pulmonary fibrosis, 90% for emphysema, and 93% for cystic fibrosis.
Emergency transplantation had a 60% 5-year survival.
Conclusion. — The thirty-five years of experience shows a consistent improvement in the results of lung transplantation which is now accepted as the only effective curative treatment for end stage lung disease.
These results show the effectiveness of our group and encourage us to continue the lung transplantation program and transmit our knowledge and training to other teams around the world.
Prof. Dr Abdul Monem HAMID
Foch University Hospital
Department of Pulmonary Medicine and Lung Transplantation
Suresnes, Paris
Université de Versailles Saint-Quentin-en-Yvelines, Paris
Paris Hospitals College of Medicine
France
Keywords
Lung Transplantation
Foch Hospital
Indication
management
survival improvement
